tag:blogger.com,1999:blog-5006185839221031362.post3504261334253834389..comments2023-09-15T16:54:53.401+02:00Comments on HEALTH ECONOMICS BLOG - Trends, Politics, Opinions etc. in biotech & pharma industry: 2010 first Risk Sharing deal with NICEUnknownnoreply@blogger.comBlogger4125tag:blogger.com,1999:blog-5006185839221031362.post-13959135633424429262010-02-02T15:57:58.627+01:002010-02-02T15:57:58.627+01:00as for the anonymous comment, many PAS are a resul...as for the anonymous comment, many PAS are a result of not meeting the CE criteria in the first place.. also, when you need to create further evidence of product value they are a good measure to obtain market access in order to continue to develop data and conduct than an ex post assessment.. so marketing tool is not the right terminologyustaginnus@hotmail.comhttps://www.blogger.com/profile/13405997204504599670noreply@blogger.comtag:blogger.com,1999:blog-5006185839221031362.post-51718594815622950692010-02-02T15:54:46.014+01:002010-02-02T15:54:46.014+01:00salisbury.. you are absolutely right, that is a di...salisbury.. you are absolutely right, that is a discount, nothing elseustaginnus@hotmail.comhttps://www.blogger.com/profile/13405997204504599670noreply@blogger.comtag:blogger.com,1999:blog-5006185839221031362.post-79637415613137735892010-01-28T15:57:00.107+01:002010-01-28T15:57:00.107+01:00Can someone please explain to me how giving away t...Can someone please explain to me how giving away the first 12-weeks of product qualifies as "risk-share"?HampsteadOwlhttps://www.blogger.com/profile/10579484010636107402noreply@blogger.comtag:blogger.com,1999:blog-5006185839221031362.post-17451617480490340252010-01-27T22:42:13.946+01:002010-01-27T22:42:13.946+01:00In today's company internal regular meeting, w...In today's company internal regular meeting, we had an introduction presentation about patient access schemes(PAS). Interesting topic but I am wondering how public reimbursement authorities in UK,Canada, Australia, US etc response to increasing use of PAS in the traditional cost effectiveness analysis(CEA). Is the result from PAS-incorporated CEA more appropriate than without-PAS CEA in terms of demosntrating economic value of study products? Will the decision made according to such analysis cause ethic issue? Or, is the PAS just used as a marketing tool for pharmaceutical companies? its future is more about negotiation tool for pharma with payers?Anonymousnoreply@blogger.com